Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Clinical Cancer Research|2021Cited by 26
Predictive value of circulating B cells and T cell subsets in melanoma patients treated with neoadjuvant ipilimumab and interferon.Arjun Khunger, Ahmad A. Tarhini, Jane Gao et al.|Journal of Clinical Oncology|2020Cited by 2
Supplementary figure legend 1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0